Clinical experience of daptomycin treatments of device-associated infections

• Autores: Ernesto Sánchez Gómez, Yolanda Arco Prados, María Mercedes Romero Alonso
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 18, Nº. 3, 2016, págs. 150-153
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction: Infections associated with microbial biofilms that form on implanted medical devices are difficult to resolve with antimicrobial chemotherapy. The aim of this study is to determine the results, in terms of effectiveness and safety, of daptomycin treatment within the habitual clinical practice when it is used for infections in patients with implanted medical devices, possibly caused by methicillin-resistant Staphylococcus aureus.

    Method: It is an observational, prospective study, from February 2013 until November 2013. Patients treated with daptomycin were followed up along the inpatient period, and beyond discharge until December 2013. The information was obtained by reviewing the electronic clinical histories and completing a data collection sheet.

    Results: 13 patients were followed up. Daptomycin was useful for our patients, having obtained a clinical improvement or total cure in 91.66% of our patients, prescribed at 10 mg/kg/day (62% prescriptions). In two cases our patients suffered from adverse drug reactions. Two possible relapses have been observed in patients treated, with medical device withdrawn in one patient only.

    Conclusion: Daptomycin, used at 10 mg/kg/day, has shown to be effective and safe in the treatment of infections in patients with implanted medical devices, avoiding its withdrawal. Nonetheless, special attention to pharmacological interaction or dose adjustment is necessary for guaranteeing the safety of the drug